Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 in Relapsing-Remitting Multiple Sclerosis
NCT01051817Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of secukinumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Started Dec 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01051817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051817.